Regeneron Pharmaceuticals Framtida tillväxt

Future kriterier kontrolleras 1/6

Regeneron Pharmaceuticals förväntas öka intäkter och intäkter med 11.7% respektive 8% per år. EPS förväntas tillväxt med 11.7% per år. Avkastningen på eget kapital förväntas bli 15% om 3 år.

Viktig information

11.7%

Tillväxttakt i vinsten

11.70%

Tillväxttakt för EPS

Biotechs vinsttillväxt	25.4%
Intäkternas tillväxttakt	8.0%
Framtida avkastning på eget kapital	14.99%
Bevakning av analytiker	Good
Senast uppdaterad	20 May 2026

Senaste uppdateringarna om framtida tillväxt

Recent updates

Seeking Alpha • May 18

REGN: Future Share Re Rating Seen Building On Underappreciated Immunology Pipeline

Analysts have modestly lifted their fair value estimate for Regeneron Pharmaceuticals to $1,030.49. The new estimate is supported by updated models that incorporate Street research pointing to stronger Dupixent contribution, an undervalued pipeline, and slightly higher assumed revenue growth, profit margins, and future P/E levels.

Uppdatering av berättelse • Mar 21

REGN: Expanding Immunology Franchise Will Support Future Upside Despite Concentration Risks

Analysts have raised their price targets on Regeneron, with the modelled fair value estimate moving from about $821.12 to $873.78 as they factor in stronger contributions from Dupixent, a higher revenue growth outlook, firmer profit margins, and a slightly lower assumed future P/E multiple. Analyst Commentary Bullish and cautious voices around Regeneron are both active, with recent research focused on how much of Dupixent's profit stream and the broader pipeline are already reflected in the share price.

Uppdatering av berättelse • Mar 07

REGN: Fair Outlook As Pipeline Optionality Offsets Product And Competition Risks

Analysts have nudged their average price target for Regeneron higher into the low $900s, reflecting views that Dupixent profitability, indication expansion, and an undervalued pipeline, including Lynozyfic, are not fully reflected in the current share price. Analyst Commentary Recent research on Regeneron centers on whether the market is giving full credit to Dupixent and the broader pipeline versus risks tied to older products and future competition.

Ny berättelse • Mar 03

Regeneron Pharmaceuticals Inc. (REGN): The Biotech Stalwart – Defensive Growth Amid Biosimilar Headwinds in 2026.

Regeneron (REGN) is currently positioned as a defensive titan in the biotechnology sector, trading at $790.76 as of the March 2, 2026, close. While the broader healthcare index has faced pressure from regulatory pricing debates, Regeneron has demonstrated relative strength, maintaining a 1.2% year-to-date gain following a robust Q4 2025 earnings beat in late January.

Uppdatering av berättelse • Feb 21

REGN: Fair Outlook As Future Pipeline And Spending Risks Remain

Analysts have raised their fair value estimate for Regeneron to $730 from $627, reflecting updated models that incorporate higher projected revenue growth, slightly stronger profit margins, and a modestly richer future P/E multiple, in line with a series of recent price target increases across the Street. Analyst Commentary Recent Street research on Regeneron has tilted positive, with a series of higher price targets from firms including Goldman Sachs, Citi, JPMorgan and others.

Uppdatering av berättelse • Feb 06

REGN: 2026 Oncology Milestones Are Expected To Drive Share Re Rating

Analysts have nudged our Regeneron Pharmaceuticals fair value estimate higher to US$1,009.20 from US$995.67, reflecting updated price targets that lean on stronger modeled revenue growth assumptions, a modestly adjusted discount rate, slightly lower profit margin expectations, and a marginally lower future P/E multiple. Analyst Commentary Recent Street research around Regeneron has leaned firmly positive, with a cluster of bullish analysts lifting price targets across a tight time window.

Uppdatering av berättelse • Jan 23

REGN: Pipeline Catalysts In 2026 Are Expected To Drive Re Rating

Analysts have lifted their fair value estimate for Regeneron Pharmaceuticals from US$890.00 to about US$995.67, reflecting higher modeled revenue growth and profit margins, alongside a slightly lower future P/E assumption and an updated discount rate. Analyst Commentary Recent research on Regeneron Pharmaceuticals has tilted clearly positive, with a series of higher price targets and supportive coverage pointing to confidence in the company’s execution, portfolio strength, and pipeline potential.

Uppdatering av berättelse • Jan 09

REGN: Core Franchises And Pipeline Will Support Balanced Upside And Concentration Risks

Analysts have raised their fair value estimate for Regeneron Pharmaceuticals from about $781 to roughly $821. This reflects updated price targets that reference a slightly lower discount rate, modestly adjusted revenue growth assumptions, a small uptick in expected profit margins, and a higher future P/E multiple supported by recent bullish research calls from several major firms.

Uppdatering av berättelse • Dec 25

REGN: Future Pipeline And Spending Risks Likely To Pressure Shares

Analysts have lifted their fair value estimate for Regeneron Pharmaceuticals to $627 from $543, citing faster expected revenue growth, improved long term profit margins, and a still compelling valuation multiple despite a modestly higher discount rate. Analyst Commentary Recent Street research on Regeneron highlights a generally positive stance on the company, with most firms reiterating or initiating Buy or Outperform ratings and lifting price targets following a strong third quarter.

Uppdatering av berättelse • Dec 11

REGN: Core Franchises And Pipeline Will Support Measured Upside Amid Ongoing Risks

Regeneron Pharmaceuticals fair value estimate has been nudged higher to approximately $781 per share from about $768, as analysts factor in stronger medium term revenue growth, expanding profit margins, and a durable innovation led pipeline that supports higher long term earnings power despite modestly lower future multiple assumptions. Analyst Commentary Recent Street research on Regeneron reflects a generally constructive stance, with most firms reiterating or initiating positive ratings while modestly recalibrating price targets around execution risks and spending needs.

Uppdatering av berättelse • Nov 27

REGN: Core Franchises And Upcoming Catalysts Will Drive Measured Upside Amid Risks

Regeneron Pharmaceuticals' analyst price target has been increased from approximately $753 to $768, as analysts highlight the company's resilient commercial base, innovative pipeline, and anticipated near-term contributions from core franchises and upcoming catalysts. Analyst Commentary Recent coverage of Regeneron Pharmaceuticals by Wall Street analysts reflects a broad consensus of confidence in the company's long-term growth drivers, while also acknowledging areas of risk that could impact future valuation and execution.

Analysartikel • Nov 19

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

The Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) share price has done very well over the last month, posting an...

Uppdatering av berättelse • Nov 12

REGN: Positive Trial Results And Approval Will Drive Continued Momentum

Regeneron's analyst price target has increased from approximately $735.72 to $753.17, as analysts cite better-than-expected quarterly results and continued strength across key product lines as drivers for the higher valuation. Analyst Commentary Bullish Takeaways Bullish analysts highlight the robust Q3 results, which surpassed expectations for both revenue and earnings.

Analysartikel • Nov 09

Regeneron Pharmaceuticals' (NASDAQ:REGN) Anemic Earnings Might Be Worse Than You Think

Regeneron Pharmaceuticals, Inc.'s ( NASDAQ:REGN ) stock showed strength, with investors undeterred by its weak earnings...

Uppdatering av berättelse • Oct 28

Pipeline Strength And Recent Developments Will Drive Premium Potential Ahead

Regeneron's analyst price target increased from $722.20 to $735.72, reflecting improved earnings results and confidence in the company's drug pipeline, according to recent analyst commentary. Analyst Commentary Following Regeneron Pharmaceuticals' recent earnings results and updates across its drug pipeline, analysts have issued a series of updated price targets and recommendations.

Uppdatering av berättelse • Sep 18

Broad Pipeline And Global Access Will Build Future Success

Regeneron Pharmaceuticals’ price target was raised to $722.20 as analysts cited continued outperformance and growth potential for Dupixent and Eylea, strong late-stage trial results in myasthenia gravis, and reinforced market leadership following competitor setbacks. Analyst Commentary Bullish analysts highlighted ongoing strength and growth potential for Dupixent and Eylea, with market share remaining dominant and robust prospects for Eylea HD.

Prognoser för vinst- och omsättningstillväxt

NasdaqGS:REGN - Analytikernas framtida uppskattningar och tidigare finansiella data (USD Millions )
Datum	Intäkter	Intäkter	Fritt kassaflöde	Kassaflöde från rörelsen	Genomsnittligt Antal analytiker
12/31/2028	18,940	5,788	6,899	7,040	22
12/31/2027	17,553	5,133	6,090	6,277	26
12/31/2026	15,880	4,088	5,055	5,696	27
3/31/2026	14,920	4,423	3,791	5,013	N/A
12/31/2025	14,343	4,505	3,765	4,979	N/A
9/30/2025	14,248	4,578	3,881	5,071	N/A
6/30/2025	14,214	4,459	3,556	4,744	N/A
3/31/2025	14,086	4,499	2,962	3,953	N/A
12/31/2024	14,202	4,413	3,539	4,421	N/A
9/30/2024	13,847	4,655	3,319	4,247	N/A
6/30/2024	13,489	4,322	3,184	4,071	N/A
3/31/2024	13,100	3,858	3,930	4,739	N/A
12/31/2023	13,117	3,954	3,668	4,594	N/A
9/30/2023	13,097	3,991	4,359	5,224	N/A
6/30/2023	12,671	4,299	3,004	4,739	N/A
3/31/2023	12,370	4,183	2,527	4,281	N/A
12/31/2022	12,173	4,338	3,398	5,015	N/A
9/30/2022	13,710	5,370	4,148	5,668	N/A
6/30/2022	14,227	5,687	7,869	8,452	N/A
3/31/2022	16,508	7,934	7,936	8,515	N/A
12/31/2021	16,072	8,075	6,529	7,081	N/A
9/30/2021	13,543	6,996	5,381	5,940	N/A
6/30/2021	12,384	6,205	1,694	2,272	N/A
3/31/2021	9,198	4,004	2,029	2,589	N/A
12/31/2020	8,497	3,513	2,004	2,618	N/A
9/30/2020	7,938	3,156	1,582	2,175	N/A
6/30/2020	7,387	2,984	2,425	2,986	N/A
3/31/2020	7,013	2,279	1,706	2,231	N/A
12/31/2019	6,558	2,116	N/A	2,430	N/A
9/30/2019	6,622	2,144	N/A	2,371	N/A
6/30/2019	6,542	2,069	N/A	2,267	N/A
3/31/2019	6,572	2,428	N/A	2,473	N/A
12/31/2018	5,146	2,444	N/A	2,195	N/A
9/30/2018	6,365	1,798	N/A	2,033	N/A
6/30/2018	6,203	1,591	N/A	1,995	N/A
3/31/2018	6,065	1,428	N/A	1,570	N/A
12/31/2017	5,872	1,199	N/A	1,307	N/A
9/30/2017	5,517	1,278	N/A	1,118	N/A
6/30/2017	5,236	1,155	N/A	1,354	N/A
3/31/2017	4,979	963	N/A	1,784	N/A
12/31/2016	4,860	896	N/A	1,486	N/A
9/30/2016	4,732	797	N/A	1,377	N/A
6/30/2016	4,649	743	N/A	1,619	N/A
3/31/2016	4,435	741	N/A	1,477	N/A
12/31/2015	4,104	636	N/A	1,331	N/A
9/30/2015	3,808	571	N/A	1,247	N/A
6/30/2015	3,396	444	N/A	519	N/A

Analytiker Framtid Tillväxt Prognoser

Intäkter kontra sparande: REGN s prognostiserade vinsttillväxt ( 11.7% per år) är över sparkvoten ( 3.5% ).

Resultat vs marknad: REGN s intäkter ( 11.7% per år) förväntas växa långsammare än marknaden för US ( 16.7% per år).

Höga tillväxtresultat: REGN s intäkter förväntas växa, men inte avsevärt.

Intäkt vs marknad: REGN s intäkter ( 8% per år) förväntas växa långsammare än marknaden för US ( 11.7% per år).

Hög tillväxtintäkter: REGN s intäkter ( 8% per år) förväntas växa långsammare än 20% per år.

Tillväxtprognoser för vinst per aktie

Framtida avkastning på eget kapital

Framtida ROE: REGN s avkastning på eget kapital förväntas bli låg om 3 år ( 15 %).

Upptäck tillväxtföretag

Företagsanalys och finansiella data Status

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2026/05/21 04:49
Aktiekurs vid dagens slut	2026/05/21 00:00
Intäkter	2026/03/31
Årlig intjäning	2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

^* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Regeneron Pharmaceuticals, Inc. bevakas av 53 analytiker. 27 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

Analytiker	Institution
Jasper Hellweg	Argus Research Company
Brian Skorney	Baird
James Birchenough	Barclays

Regeneron Pharmaceuticals Framtida tillväxt

Future kriterier kontrolleras 1/6

Viktig information

Senaste uppdateringarna om framtida tillväxt

Consensus EPS estimates increase by 15%

Price target decreased by 7.4% to US$738

Price target decreased by 7.0% to US$797

Consensus EPS estimates fall by 15%

Price target decreased by 8.6% to US$808

Recent updates

Regeneron: Time To Forget Fianlimab (Rating Upgrade)

Regeneron Phase 3 Combo Trial in Advanced Melanoma Misses Primary Goal

Regeneron Pharmaceuticals Provides Update on Phase 3 Trial of Fianlimab Combination in First-Line Unresectable or Metastatic Melanoma

Upcoming dividend of US$0.94 per share

Regeneron Pharmaceuticals, Inc. and Sanofi Demonstrate Dupixent Shows Improved Esophageal Function in Eosinophilic Esophagitis Phase 4 Trial

REGN: Expanding Immunology And Gene Therapy Will Support Future Upside

First quarter dividend of US$0.94 announced

First quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behind

Regeneron Pharmaceuticals, Inc. announces Quarterly dividend, payable on June 04, 2026

Regeneron Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2026

Regeneron Pharmaceuticals, Inc. And Sanofi Announces Dupixent Approved In U.S. For Young Children With Uncontrolled Chronic Spontaneous Urticaria

Regeneron Pharmaceuticals Inc Receives FDA Approval for Otarmeni Gene Therapy for Genetic Hearing Loss

Regeneron Pharmaceuticals, Inc. Demonstrates Cemdisiran Rapid, Deep And Sustained Disease Control In Generalized Myasthenia Gravis Phase 3 Trial

REGN: Fair Outlook As Mixed Pipeline And Product Trends Shape Prospects

Sanofi and Regeneron's Dupixent Approves in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria

Regeneron Pharmaceuticals, Inc. and Sanofi Receive European Commission Approval for Dupixent to Treat Chronic Spontaneous Urticaria in Children Aged 2 to 11 Years

REGN: Future Share Re Rating Seen Building On Underappreciated Immunology Pipeline

Regeneron Pharmaceuticals, Inc. Announces That the U.S. Food and Drug Administration Approves the Extension of Dosing Intervals for Eylea Hd

Regeneron Pharmaceuticals, Inc. to Report Q1, 2026 Results on Apr 29, 2026

Sanofi and Regeneron Receive Approval for Dupixent in Japan as First Targeted Medicine to Treat Adults with Bullous Pemphigoid

REGN: Expanding Immunology Franchise Will Support Future Upside Despite Concentration Risks

REGN: Fair Outlook As Pipeline Optionality Offsets Product And Competition Risks

Regeneron Pharmaceuticals Inc. (REGN): The Biotech Stalwart – Defensive Growth Amid Biosimilar Headwinds in 2026.

Regeneron Pharmaceuticals, Inc. and Sanofi Announce Positive CHMP Opinion for Dupixent in Treating Chronic Spontaneous Urticaria in Children Aged 2 to 11 Years

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Dupixent (Dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (Afrs)

REGN: Fair Outlook As Future Pipeline And Spending Risks Remain

Independent Director notifies of intention to sell stock

Regeneron Pharmaceuticals, Inc. Announces Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva

Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy

REGN: 2026 Oncology Milestones Are Expected To Drive Share Re Rating

Regeneron Pharmaceuticals, Inc. Announces Upcoming Presentations from Its Ophthalmology Portfolio and Pipeline At the Virtual Angiogenesis Annual Meeting on February 7, 2026

Fourth quarter dividend of US$0.94 announced

Full year 2025 earnings: EPS exceeds analyst expectations

REGN: Pipeline Catalysts In 2026 Are Expected To Drive Re Rating

Anavex Life Sciences Corp Appoints Dr. Wolfgang Liedtke as Senior Vice President, Global Head of Neurology

REGN: Core Franchises And Pipeline Will Support Balanced Upside And Concentration Risks

Regeneron Pharmaceuticals, Inc. to Report Q4, 2025 Results on Jan 30, 2026

Independent Director exercised options to buy US$2.3m worth of stock.

REGN: Future Pipeline And Spending Risks Likely To Pressure Shares

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Approval in Japan for Children Aged 6 to 11 Years with Bronchial Asthma

Alvotech and Teva Pharmaceuticals Reach a Settlement and License Agreement with Regeneron Pharmaceuticals Inc

Co-Founder exercised options and sold US$23m worth of stock

REGN: Core Franchises And Pipeline Will Support Measured Upside Amid Ongoing Risks

Regeneron Pharmaceuticals, Inc. Announces Lynozyfic Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment

REGN: Core Franchises And Upcoming Catalysts Will Drive Measured Upside Amid Risks

Executive VP exercised options and sold US$2.3m worth of stock

Regeneron Pharmaceuticals, Inc. and Sanofi Announce European Commission Approves Dupixent (Dupilumab) for the Treatment of Moderate-To-Severe Chronic Spontaneous Urticaria (CSU)

Regeneron Pharmaceuticals Announces FDA Approval Of EYLEA HD Injection 8 Mg For Treatment Of Macular Edema Following Retinal Vein Occlusion And Monthly Dosing Across Approved Indications

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

European Commission Approves the Pd-1 Inhibitor Libtayo of Regeneron Pharmaceuticals, Inc

Upcoming dividend of US$0.88 per share

REGN: Positive Trial Results And Approval Will Drive Continued Momentum

Regeneron Pharmaceuticals' (NASDAQ:REGN) Anemic Earnings Might Be Worse Than You Think

Regeneron Pharmaceuticals, Inc. Announces Detailed Positive Phase 2 Trial Results Evaluating Two Novel Investigational Factor Xi Antibodies - Regn7508cat and Regn9933a2

Insider exercised options and sold US$2.2m worth of stock

Third quarter 2025 earnings: EPS and revenues exceed analyst expectations

Regeneron Pharmaceuticals, Inc. announces Quarterly dividend, payable on December 05, 2025

Consensus EPS estimates increase by 15%

Pipeline Strength And Recent Developments Will Drive Premium Potential Ahead

Regeneron Pharmaceuticals, Inc. Announces European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion for Libtayo (Cemiplimab)

Regeneron Pharmaceuticals, Inc. Announces Updated Data for Their Investigational Gene Therapy Db-Oto for Profound Genetic Hearing Loss

Regeneron Pharmaceuticals, Inc. Announces That the U.S. Food and Drug Administration Approves the PD-1 Inhibitor Libtayo(Cemiplimab-Rwlc) as an Adjuvant Treatment for Adult Patients

Regeneron Pharmaceuticals, Inc. to Report Q3, 2025 Results on Oct 28, 2025

U.S. Food and Drug Administration Approves Evkeeza (Evkeeza-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol

Regeneron Pharmaceuticals, Inc. and Sanofi Announces That European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) Adopts Positive CHMP Opinion

Broad Pipeline And Global Access Will Build Future Success

Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva, Demonstrating That Garetosmab Prevents Greater Than 99% of Abnormal Bone Formation

Regeneron Pharmaceuticals, Inc. Announces Five-Year Follow-Up Results on Overall Survival from the Phase 3 Empower-Lung 3 Trial

Regeneron Pharmaceuticals, Inc. Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-In-Class Antibody-Blockers of Cat and Birch Allergies

Regeneron Pharmaceuticals, Inc. Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis